Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 2, 2013, Pages 690-695

  Shi, Tie Jun Sten ^a,b,c   Zhang, Ming Dong ^b,c   Zeberg, Hugo ^c   Nilsson, Johanna ^c   Grünler, Jacob ^a   Liu, Su Xing ^c   Xiang, Qiong ^b,c   Persson, Jonas ^c   Fried, Kaj J ^c   Catrina, Sergiu Bogdan ^a   Watanabe, Masahiko ^d   Århem, Peter ^c   Brismar, Kerstin ^a   Hökfelt, Tomas G M ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HARBIN INSTITUTE OF TECHNOLOGY   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Electrophysiology; Neurodegeneration; Neuropeptide

Indexed keywords

PHOSPHOLIPASE C BETA3; REACTIVE OXYGEN METABOLITE; UBIDECARENONE;

ALLODYNIA; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DOWN REGULATION; HYPOALGESIA; MALE; MOUSE; NERVE CONDUCTION; NEUROCHEMISTRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; SCIATIC NERVE; SENSORY DYSFUNCTION; SPINAL GANGLION; STANDARD;

AGE FACTORS; ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; ELECTRIC STIMULATION; GANGLIA, SPINAL; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NEURAL CONDUCTION; NEURONS; PERIPHERAL NERVOUS SYSTEM DISEASES; PHOSPHOLIPASE C BETA; RECEPTORS, LEPTIN; SCIATIC NERVE; STATISTICS, NONPARAMETRIC; UBIQUINONE;

ANIMALIA; MUS;

EID: 84872185416     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220794110     Document Type: Article

References (94)

1. Boulton AJ, et al.; American Diabetes Association (2005) Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 28(4):956-962.
2. Sima AA (2003) New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 60(11):2445-2464.
3. Tomlinson DR, Gardiner NJ (2008) Diabetic neuropathies: components of etiology. J Peripher Nerv Syst 13(2):112-121.
4. Zochodne DW (2008) Diabetic polyneuropathy: An update. Curr Opin Neurol 21(5):527-533.
5. Feldman EL, et al. (2005) The Diabetes Mellitus Manual, ed Inzucchi SE (McGraw-Hill, New York), pp 366-384.
6. Pirart J (1965) Diabetic neuropathy: A metabolic or a vascular disease? Diabetes 14:1-9.
7. Thomas PK, Eliasson SG (1975) Peripheral Neuropathy, eds Dyck PJ, Thomas PK, Lampert EH (Saunders, Philadelphia), pp 956-981.
8. Hendriksen PH, Oey PL, Wieneke GH, Bravenboer B, Banga JD (1992) Subclinical diabetic neuropathy: Similarities between electrophysiological results of patients with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35(7):690-695.
9. Sima AA, Kamiya H (2006) Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann N Y Acad Sci 1084:235-249.
10. Feldman EL, et al. (2002) Diabetic Peripheral and Autonomic Neuropathy. Contemporary Endocrinology (Humana, Totowa, NJ).
11. Said G, Goulon-Goeau C, Slama G, Tchobroutsky G (1992) Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus. A clinical and pathological study. N Engl J Med 326(19):1257-1263.
12. Cheng HT, Dauch JR, Hayes JM, Hong Y, Feldman EL (2009) Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. J Neuropathol Exp Neurol 68(11):1229-1243.
13. Hummel KP, Dickie MM, Coleman DL (1966) Diabetes, a new mutation in the mouse. Science 153(3740):1127-1128.
14. Sullivan KA, et al. (2007) Mouse models of diabetic neuropathy. Neurobiol Dis 28(3):276-285.
15. Ayaz M, Tuncer S, Okudan N, Gokbel H (2008) Coenzyme Q(10) and alpha-lipoic acid supplementation in diabetic rats: Conduction velocity distributions. Methods Find Exp Clin Pharmacol 30(5):367-374.
16. Behse F, Buchthal F, Carlsen F (1977) Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 40(11):1072-1082.
17. Kishi M, Tanabe J, Schmelzer JD, Low PA (2002) Morphometry of dorsal root ganglion in chronic experimental diabetic neuropathy. Diabetes 51(3):819-824.
18. Lennertz RC, Medler KA, Bain JL, Wright DE, Stucky CL (2011) Impaired sensory nerve function and axon morphology in mice with diabetic neuropathy. J Neurophysiol 106(2):905-914.
19. Robertson DM, Sima AA (1980) Diabetic neuropathy in the mutant mouse [C57BL/ks (db/db)]: A morphometric study. Diabetes 29(1):60-67.
20. Sima AA, Robertson DM (1978) Peripheral neuropathy in mutant diabetic mouse [C57BL/Ks (db/db)]. Acta Neuropathol 41(2):85-89.
21. Hildebrand J, Joffroy A, Graff G, Coërs C (1968) Neuromuscular changes with alloxan hyperglycemia. Electrophysiological, biochemical, and histological study in rats. Arch Neurol 18(6):633-641.
22. Preston GM (1967) Peripheral neuropathy in the alloxan-diabetic rat. J Physiol 189(2):49P-50P.
23. Valls-Canals J, Povedano M, Montero J, Pradas J (2002) Diabetic polyneuropathy. Axonal or demyelinating? Electromyogr Clin Neurophysiol 42(1):3-6.
24. Dyck PJ, et al. (1981) Acute hyperosmolar hyperglycemia causes axonal shrinkage and reduced nerve conduction velocity. Exp Neurol 71(3):507-514.
25. Sima AA, Bouchier M, Christensen H (1983) Axonal atrophy in sensory nerves of the diabetic BB-Wistar rat: A possible early correlate of human diabetic neuropathy. Ann Neurol 13(3):264-272.
26. McCarthy BG, et al. (1995) Cutaneous innervation in sensory neuropathies: Evaluation by skin biopsy. Neurology 45(10):1848-1855.
27. Zochodne DW, Verge VM, Cheng C, Sun H, Johnston J (2001) Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. Brain 124(Pt 11):2319-2334.
28. Burnand RC, Price SA, McElhaney M, Barker D, Tomlinson DR (2004) Expression of axotomy-inducible and apoptosis-related genes in sensory nerves of rats with experimental diabetes. Brain Res Mol Brain Res 132(2):235-240.
29. Brussee V, et al. (2008) Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes 57(6):1664-1673.
30. Hökfelt T, Zhang X, Wiesenfeld-Hallin Z (1994) Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci 17(1):22-30.
31. Costigan M, et al. (2002) Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci 3:16.
32. Xiao HS, et al. (2002) Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci USA 99(12):8360-8365.
33. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM (2004) Diabetic somatic neuropathies. Diabetes Care 27(6):1458-1486.
34. Pop-Busui R, Sima A, Stevens M (2006) Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 22(4):257-273.
35. Vincent AM, Callaghan BC, Smith AL, Feldman EL (2011) Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nat Rev Neurol 7(10):573-583.
36. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ (2010) Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 19(4):535-554.
37. Littarru GP, Tiano L, Belardinelli R, Watts GF (2011) Coenzyme Q(10), endothelial function, and cardiovascular disease. Biofactors 37(5):366-373.
38. Quinzii CM, Hirano M (2011) Primary and secondary CoQ(10) deficiencies in humans. Biofactors 37(5):361-365.
39. Bentinger M, Brismar K, Dallner G (2007) The antioxidant role of coenzyme Q. Mitochondrion 7(Suppl):S41-S50.
40. Zhang Y, Turunen M, Appelkvist EL (1996) Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells. J Nutr 126(9):2089-2097.
41. Vincent AM, Edwards JL, Sadidi M, Feldman EL (2008) The antioxidant response as a drug target in diabetic neuropathy. Curr Drug Targets 9(1):94-100.
42. Golbidi S, Ebadi SA, Laher I (2011) Antioxidants in the treatment of diabetes. Curr Diabetes Rev 7(2):106-125.
43. Koplovitch P, Minert A, Devor M (2012) Spontaneous pain in partial nerve injury models of neuropathy and the role of nociceptive sensory cover. Exp Neurol 236(1):103-111.
44. Brismar T, Sima AA (1981) Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat: Potential clamp analysis. Acta Physiol Scand 113(4):499-506.
45. Sima AA, Zhang W, Li ZG, Murakawa Y, Pierson CR (2004) Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 53(6):1556-1563.
46. Sima AA, et al. (2000) A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats. Diabetologia 43(6):786-793.
47. Moore JW, Joyner RW, Brill MH, Waxman SD, Najar-Joa M (1978) Simulations of conduction in uniform myelinated fibers. Relative sensitivity to changes in nodal and internodal parameters. Biophys J 21(2):147-160.
48. Barrett AM, et al. (2007) Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Med 8(Suppl 2):S50-S62.
49. Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22(4):340-349.
50. Currie CJ, et al. (2007) The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 24(2):187-194.
51. Martin CL, et al.; DCCT/EDIC Research Group (2006) Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29(2):340-344.
52. Kamiya H, Murakawa Y, Zhang W, Sima AA (2005) Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 21(5):448-458.
53. Sidenius P, Jakobsen J (1980) Reduced perikaryal volume of lower motor and primary sensory neurons in early experimental diabetes. Diabetes 29(3):182-186.
54. Shimoshige Y, et al. (2009) Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats. Brain Res 1247:182-187.
55. Tandrup T (2004) Unbiased estimates of number and size of rat dorsal root ganglion cells in studies of structure and cell survival. J Neurocytol 33(2):173-192.
56. Kamiya H, Zhang W, Sima AA (2006) Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats. Diabetologia 49(11):2763-2774.
57. Chattopadhyay M, Walter C, Mata M, Fink DJ (2009) Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 132(Pt 4):879-888.
58. Huang TJ, Sayers NM, Verkhratsky A, Fernyhough P (2005) Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats. Exp Neurol 194(1):279-283.
59. Srinivasan S, Stevens M, Wiley JW(2000) Diabetic peripheral neuropathy: Evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 49(11):1932-1938.
60. Brewster WJ, Fernyhough P, Diemel LT, Mohiuddin L, Tomlinson DR (1994) Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci 17(8):321-325.
61. Hellweg R, Raivich G, Hartung HD, Hock C, Kreutzberg GW(1994) Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 130(1):24-30.
62. Tomlinson DR, Fernyhough P, Diemel LT (1996) Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci 351(1338):455-462.
63. Zochodne DW (1996) Neurotrophins and other growth factors in diabetic neuropathy. Semin Neurol 16(2):153-161.
64. Yasuda H, et al. (2003) Diabetic neuropathy and nerve regeneration. Prog Neurobiol 69(4):229-285.
65. Han SK, Mancino V, Simon MI (2006) Phospholipase Cbeta 3 mediates the scratching response activated by the histamine H1 receptor on C-fiber nociceptive neurons. Neuron 52(4):691-703.
66. Shi TJ, et al. (2008) Phospholipase Cbeta3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain. Proc Natl Acad Sci USA 105(50):20004-20008.
67. XieW, et al. (1999) Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids. Proc Natl Acad Sci USA 96(18):10385-10390.
68. Joseph EK, Bogen O, Alessandri-Haber N, Levine JD (2007) PLC-beta 3 signals upstream of PKC epsilon in acute and chronic inflammatory hyperalgesia. Pain 132(1-2):67-73.
69. Bennett J, Weeds A (1986) Calcium and the cytoskeleton. Br Med Bull 42(4):385-390.
70. Veves A, Backonja M, Malik RA (2008) Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options. Pain Med 9(6):660-674.
71. Petit WA, Jr., Upender RP (2003) Medical evaluation and treatment of diabetic peripheral neuropathy. Clin Podiatr Med Surg 20(4):671-688.
72. Hadj Tahar A (2005) Pregabalin for peripheral neuropathic pain. Issues Emerg Health Technol (67):1-4.
73. Bril V, et al.; American Academy of Neurology; American Asociation of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation (2011) Evidence-based guideline: Treatment of painful diabetic neuropathy - Report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve 43(6):910-917.
74. Israili ZH (2011) Advances in the treatment of type 2 diabetes mellitus. Am J Ther 18(2):117-152.
75. Zochodne DW (2012) Reversing neuropathic deficits. J Peripher Nerv Syst 17(Suppl 2):4-9.
76. Rathur HM, Boulton AJ (2007) The neuropathic diabetic foot. Nat Clin Pract Endocrinol Metab 3(1):14-25.
77. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA (2003) The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26(6):1790-1795.
78. Habib AA, Brannagan TH, 3rd (2010) Therapeutic strategies for diabetic neuropathy. Curr Neurol Neurosci Rep 10(2):92-100.
79. Frier BM (2004) Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract 65(Suppl 1):S47-S52.
80. Inzucchi SE, et al. (2012) Management of hyperglycemia in type 2 diabetes: A patientcentered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364-1379.
81. Christianson JA, Ryals JM, Johnson MS, Dobrowsky RT, Wright DE (2007) Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice. Neuroscience 145(1):303-313.
82. Unger JW, Klitzsch T, Pera S, Reiter R (1998) Nerve growth factor (NGF) and diabetic neuropathy in the rat: Morphological investigations of the sural nerve, dorsal root ganglion, and spinal cord. Exp Neurol 153(1):23-34.
83. Walwyn WM, et al. (2006) HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy. Exp Neurol 198(1):260-270.
84. Wiggin TD, et al. (2008) Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice. Endocrinology 149(10):4928-4937.
85. Sima AA, et al. (2001) C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia 44(7):889-897.
86. Ekberg K, et al. (2007) C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 30(1):71-76.
87. Wahren J, Kallas A, Sima AA (2012) The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 61(4):761-772.
88. Eberhardt MJ, et al. (2012) Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): A possible mechanism of metabolic neuropathies. J Biol Chem 287(34):28291-28306.
89. Watts GF, et al. (2002) Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 45(3):420-426.
90. Hernández-Ojeda J, et al. (2012) The effect of ubiquinone in diabetic polyneuropathy: A randomized double-blind placebo-controlled study. J Diabetes Complications 26(4):352-358.
91. Persson MF, et al. (2012) Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes. Diabetologia 55(5):1535-1543.
92. Shi TJ, et al. (2001) Effect of peripheral nerve injury on dorsal root ganglion neurons in the C57 BL/6J mouse: Marked changes both in cell numbers and neuropeptide expression. Neuroscience 105(1):249-263.
93. Dagerlind Å, Friberg K, Bean AJ, Hökfelt T (1992) Sensitive mRNA detection using unfixed tissue: Combined radioactive and non-radioactive in situ hybridization histochemistry. Histochemistry 98(1):39-49.
94. Shapiro S, Wilk M (1965) An analysis of variance test for normality (complete samples). Biometrika 52(3/4):591-611.